TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00968942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
Study: NCT01895647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
Study: NCT03870022

Intervention type: DEVICE
Group type: OTHER
Intervention: Pivot Breath Sensor System
Description: Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
Study: NCT02697422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based peer health coach intervention
Description: The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
Study: NCT02273453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songha® Night

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03030209

Intervention type: PROCEDURE
Intervention: Distal pancreatectomy
Description: Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
Study: NCT02555098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire contact lenses
Description: Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A contact lenses
Description: Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
Study: NCT03186924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a STAND for health
Description: The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
Study: NCT01982227

Intervention type: DRUG
Intervention: indocyanine green
Description: intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
Study: NCT03501277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study: NCT03870022

Intervention type: DEVICE
Group type: OTHER
Intervention: Similar Carbon Monoxide breath sensor system
Description: Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
Study: NCT04101422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 1
Description: Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 2
Description: Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 3
Description: Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 4
Description: Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
Study: NCT03505242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchial blocker for BB group
Description: Using bronchial blocker to block right middle lower lobe during surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen tube for DLT group
Description: Using double lumen tube to achieve single lung ventilation during surgery.
Study: NCT01565746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
Study: NCT04290546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting day +15, every 14 days for 8 total doses via IV per protocol
Study: NCT01733797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wooden spatula
Description: Lollipop sticks placed between incisors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therabite
Description: Hand held device placed in mouth that exercises the jaw
Study: NCT01525901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin-Like Growth Factor-1 (IGF-1)
Description: IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Saline solution will be administered for three months subcutaneously.
Study: NCT03745963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Description: Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% oral sucrose
Description: Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
Study: NCT03916393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 20 mg
Description: PF-06651600 in four (4) different oral formulations will be administered in different periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 20 mg
Description: PF-06651600 in four (4) different oral formulations will be administered in different periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 20 mg
Description: PF-06651600 in four (4) different oral formulations will be administered in different periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 20 mg
Description: PF-06651600 in four (4) different oral formulations will be administered in different periods.

Intervention type: OTHER
Group type: OTHER
Intervention: Bitrex solution
Description: Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
Study: NCT00707330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Prolonged release tablet, 500 mg, 1 tablet a day for a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Prolonged release tablet, 500 mg, 1 tablet a day for a week
Study: NCT02316015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infatrini® or Infatrini Peptisorb®
Study: NCT02849496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy
Study: NCT01565746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
Study: NCT02849496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT03501277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study: NCT00850499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: rituximab 375mg/m2 on Day 1 of every 35-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
Study: NCT02849496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01864135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI (Magnetom Verio 3T, Erlangen, Germany)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)
Study: NCT01486680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass
Description: An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve gastrectomy
Description: Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
Study: NCT02614794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral dose twice daily
Study: NCT00552305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
Study: NCT02018250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB4 DMS
Description: Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB4 DMS
Description: Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB4 DMS
Description: Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB4 DMS
Description: Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
Study: NCT00195845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT04332809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline-gentamicin irrigation
Description: Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline irrigation
Description: Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
Study: NCT01915628

Intervention type: DEVICE
Intervention: BioMatrix Flex
Description: Percutaneous coronary intervention
Study: NCT03501277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study: NCT02018250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
Study: NCT03701789

Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: Effect of Baricitinib on vBMD measured by HR-pQCT
Study: NCT04977544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vert
Description: On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
Study: NCT03865342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Coach DPP
Description: Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
Study: NCT03501277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322-4833 BL
Description: SYR-322-4833 BL FDC tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322-4833 BL
Description: SYR-322-4833 BL FDC tablets.
Study: NCT02944747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & paper based calendar
Description: The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & SMS system
Description: The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & smart-phone application
Description: The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
Study: NCT04438135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated open application test
Description: parallel application of two different types of lotion with and without aluminium.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repeated open application test
Description: parallel application of two different types of lotion with and without aluminium.
Study: NCT01558687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug (including placebo)
Description: Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
Study: NCT00693186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBVaxPRO® 5 µg / 0.5 mL
Description: 5 µg / 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix B® 10 µg / 0.5 mL
Description: 10 µg
Study: NCT00968734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colecalciferol
Description: 50.000UI single oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colecalciferol
Description: 50.000UI single oral dose
Study: NCT02849496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies